
CAMP Stock Forecast & Price Target
CAMP Analyst Ratings
Bulls say
Camp4 Therapeutics is attractive fundamentally because CMP-002 targets SYNGAP1, a rare genetic neurological disorder with ~11K U.S. patients, no approved drugs, and severe unmet needs in cognition, communication, seizures, and adaptive function. Its ASO-based RAP platform is clinically validated, programmable, and designed to restore SYNGAP1 expression without altering DNA, while preclinical data show dose-dependent mRNA normalization, near wild-type protein restoration, and seizure reduction in humanized models plus broad brain exposure in NHPs. Financially, the company ended 2Q:26 with $86 million in cash, added $50 million in financing, and is estimated to have ~$133 million pro forma cash to fund operations through YE:28, supporting an important Phase I/II study expected to start in 2H:26.
Bears say
Camp4 Therapeutics is burdened by a weak fundamental setup because it remains a development-stage company with no revenue-producing products, no anticipated profitability for several years, and a continuing cash burn that likely forces additional debt or equity financing. The need for long and expensive clinical development, combined with the risk of dilutive capital raises, restrictive covenants, and uncertain access to funding under market-dependent conditions, makes execution and shareholder returns highly uncertain. Competitive pressure is also severe, as stronger SYNGAP1 programs from better-resourced rivals raise the bar for success, while clinical, regulatory, and intellectual property risks could further delay or derail CMP-002, CMP-CPS-001, and CMP-SYNGAP.
This aggregate rating is based on analysts' research of CAMP4 Therapeutics Corp and is not a guaranteed prediction by Public.com or investment advice.
CAMP Analyst Forecast & Price Prediction
Start investing in CAMP
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About CAMP4 Therapeutics Corp (CAMP) Forecast
CAMP Analyst Forecast & Price Prediction
Start investing in CAMP
Order type
Buy in
Order amount
Est. shares
0 shares